IDAI

Trust Stamp Inc (NASDAQ:IDAI, ISE:AIID) saw its net recognized revenue rise 39% rise in Q1, fueled by a bank client contract amendment, with revenue from two new customers set to begin in Q2. Net recognized revenue rose to $757,000 from $545,000 in the year-ago period, with the company attributing the gain primarily to a contract amendment with an S&P 500 bank customer that added $236,000 in recognized revenue compared to the prior-year quarter. The company noted that revenue from services delivered to its newest customers in Q1 was not included in the recognized revenue figure and will generate billable revenue in the second quarter and beyond. “The increase in recognized revenue in Q1 reflects a high level of continued performance on our historic engagements in parallel to our work with two new major clients that we anticipate will result in significant billable revenue in Q2 and beyond,” CEO Gareth Genner told shareholders. Total operating expenses for the quarter were $3.03 million, up from $2.71 million a year earlier, an increase of $318,000. Trust Stamp said the rise included one-time acquisition costs related to Lexverify, development spending on its Wallet of Wallets (WoW) product, timing differences in restricted stock unit expense recognition, and higher cost of sales tied to the revenue increase. “Our pipeline of substantial revenue prospects has continued to grow and mature and we are seeing significant interest in our WoW which will launch once there is resolution of the continuing legislative uncertainties regarding stablecoin governance,” Genner added. Comprehensive loss for the quarter was $2.23 million, compared to $2.16 million in the first quarter of 2025. Basic and diluted net loss per share narrowed to $0.42 from $0.89 in the year-ago period. Cash and cash equivalents stood at $3.89 million at the end of March 2026.

Revenue: US$3.08m (down 32% from FY 2023). Net loss: US$12.5m (loss widened by 64% from FY 2023). US$11.36 loss per share. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 47%. Earnings per share (EPS) missed analyst estimates by 30%. The company's shares are down 13% from a week ago. You should learn about the 6 warning signs we've spotted with T Stamp (including 3 which don't sit too well with us). Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.